Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
BACKGROUND
Depression is a frequent comorbid condition in patients with Alzheimer's disease (AD). In the present study, we reported the effect of additional donepezil treatment for patients with geriatric depression who exhibited cognitive deficit and were diagnosed with AD during treatment for depression.


METHODS
The present retrospective study investigated 14 AD outpatients who were diagnosed with geriatric depression at first and received antidepressant treatment. When apparent cognitive decline was observed, all of them were diagnosed with AD and received donepezil (5 mg/day) for at least 1 year. All patients underwent periodic examination of cognitive function (Mini-Mental State Examination, Rorschach Cognitive Index) and clinical evaluation (Clinical Dementia Rating). The 14 patients were classified into three groups according to their treatment course: (i) 'A' group, patients who showed cognitive impairment during a long course of treatment for depression; (ii) 'B' group, patients who showed cognitive impairment at an early stage of treatment for depression and started to take additional donepezil at least 20 months after the first examination; and (iii) 'C' group, patients who showed cognitive impairment at an early stage of treatment for depression and began taking additional donepezil within 10 months of the first examination. The clinical feature and treatment effects were examined for each group.


RESULTS
At 1 and 2 years after the start of treatment, the proportion of patients who had improved or maintained their Clinical Dementia Rating score was higher in 'A' and 'C' groups than in 'B' group. In 'B' group, additional donepezil treatment commenced later than in the other groups. Therefore, donepezil had an insufficient curative effect.


CONCLUSIONS
The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression.
Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.|Okamoto Clinic, Kikugawa, Shizuoka, Japan.
Jun
J
Inoue
Okamoto Clinic, Kikugawa, Shizuoka, Japan.|Department of Psychiatry, Kanarekai Koujin Hospital, Nagoya, Shizuoka, Japan.
Ryoichi
R
Hoshino
Okamoto Clinic, Kikugawa, Shizuoka, Japan.
Hidenori
H
Nojima
Department of Psychiatry, Numazu Senbon Hospital, Numazu City, Shizuoka, Japan.
Wataru
W
Ishida
Okamoto Clinic, Kikugawa, Shizuoka, Japan.
Norio
N
Okamoto
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003071:Cognition; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy*; D000077265:Donepezil; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D018697:Nootropic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil
Alzheimer's disease; cognitive function; donepezil; geriatric depression